NC Biotech Meets Challenges Large and Small - FOX 42: Omaha News, Sports and Weather; |

NC Biotech Meets Challenges Large and Small

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE North Carolina Biotechnology Center

NC Pavilion Panels at BIO 2014 Showcase Breadth of State's Industry

RESEARCH TRIANGLE PARK, N.C., June 23, 2014 /PRNewswire-USNewswire/ -- Proof that companies large and small thrive in North Carolina's life science industry will be on display at the 2014 BIO International Convention in San Diego this week.

The largest companies – those in production and manufacturing – produce some of the most critical vaccines, medicines and industrial enzymes. The smallest companies – start up research and development teams – develop novel technologies that lead to tomorrow's scientific breakthroughs. Both benefit from a rich bioscience community and highly educated workforce in North Carolina.

A biomanufacturing panel will shine a light on the unique North Carolina facilities using bio-based processes. Topics include the rigors of hiring, challenges in bioprocessing, and the future course of this specialized function. The speakers include:

  • Machelle Sanders, vice president of manufacturing and general manager, Biogen Idec in Research Triangle Park
  • David P. Stewart, director, operational excellence, Accelerated Delivery Programme consultant, Global Manufacturing & Supply, GlaxoSmithKline in Zebulon
  • Nat Hentz, assistant director, analytical lab, BTEC, North Carolina State University

The panel will be moderated by Bill Bullock, vice president, Bioscience Industrial Development at NCBiotech. It is Tuesday, June 24 from 1:30 to 2:30 p.m.

A second panel is "Innovative Business/Financing Models to Accelerate Product Development." From licensing deals to IPO, the panelists will talk about what worked for their companies. Panelists include:

  • Steve Butts, president, COO & co-founder, Aerial BioPharma. Aerial out-licensed its narcolepsy drug for $125M upfront plus milestones/royalties
  • Mike Grey, president & CEO, Lumena Pharmaceuticals and venture partner, Pappas Ventures. Lumena sold to Shire for $260M+ in May 2014
  • Jeff Wolf, founder & CEO, Heat Biologics. Jeff completed a successful IPO in July 2013

The panel will be moderated by Peter Ginsberg, vice president for Business and Technology Development at NCBiotech, which has invested in 20 emerging biopharma companies through NCBiotech's loan programs during the past fiscal year alone.  The panel is Wednesday, June 25 from 3:30 to 4:30 p.m.

The North Carolina pavilion features a full presentation schedule with talks from the pavilion's two-dozen-plus sponsors. Visit us in San Diego at Booth #1727.

For more information contact Jim Shamp, NCBiotech's director of public relations, at 919-541-9366 or visit

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

General Information:

Phone: 402-554-4282
Fax: 402-554-4279

Can't find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KPTM. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.